文献速递心脑血管急症

Bococizumab在高危患者中的心血管疗效与安全性

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
PubMed 文献 · N Engl J Med · 2017-03-17
一句话结论在两项平行随机试验中,PCSK9抑制剂bococizumab在低危患者中主要心血管事件无获益,但在高危患者中有显著获益。

两项平行、跨国随机试验共纳入27,438例心血管高危患者,随机接受bococizumab 150 mg皮下注射每2周1次或安慰剂,93%基线已用他汀。因出现高滴度抗药抗体,申办方决定停止bococizumab开发,试验提前终止,中位随访10个月。14周时bococizumab组LDL胆固醇较基线平均变化-56.0%,安慰剂组+2.9%,组间差异-59.0个百分点(P<0.001)。低危短程试验主要心血管事件两组各173例(HR 0.99;95%CI 0.80-1.22;P=0.94);高危长程试验分别为179例和224例(HR 0.79;95%CI 0.65-0.97;P=0.02);合并试验HR 0.88(95%CI 0.76-1.02;P=0.08)。注射部位反应bococizumab组10.4% vs 安慰剂组1.3%(P<0.001)。

要点

  • 高危长程试验(基线LDL≥100 mg/dL,中位随访12个月)bococizumab组主要心血管事件179例 vs 安慰剂组224例,HR 0.79(95%CI 0.65-0.97;P=0.02)。
  • 低危短程试验(基线LDL≥70 mg/dL,中位随访7个月)bococizumab组与安慰剂组主要心血管事件各173例,HR 0.99(95%CI 0.80-1.22;P=0.94)。
  • 合并两项试验主要终点HR 0.88(95%CI 0.76-1.02;P=0.08),未达统计学显著。
  • 14周时bococizumab组LDL胆固醇较基线平均变化-56.0%,安慰剂组+2.9%,组间差异-59.0个百分点(P<0.001)。
  • 注射部位反应bococizumab组10.4% vs 安慰剂组1.3%(P<0.001);因出现高滴度抗药抗体,试验提前终止。

适用人群与场景

  • 两项平行、跨国随机试验共纳入27,438例心血管高危患者,93%基线接受他汀治疗。
  • 低危短程试验纳入基线LDL胆固醇≥70 mg/dL(1.8 mmol/L)患者,中位随访7个月。
  • 高危长程试验纳入基线LDL胆固醇≥100 mg/dL(2.6 mmol/L)患者,中位随访12个月。

处置流程与药物剂量

  • bococizumab 150 mg皮下注射每2周1次,用于心血管高危患者;对照为安慰剂。

研究设计与关键结果

  • 研究类型为两项平行、跨国随机对照试验(SPIRE-1和SPIRE-2),合并样本量27,438例,中位随访10个月;因出现高滴度抗药抗体,申办方决定停止bococizumab开发,试验提前终止。
  • 14周时bococizumab组LDL胆固醇较基线平均变化-56.0%,安慰剂组+2.9%,组间差异-59.0个百分点(P<0.001),bococizumab组较基线中位降低64.2%(P<0.001)。
  • 低危短程试验(基线LDL≥70 mg/dL,中位随访7个月)主要心血管事件bococizumab组173例 vs 安慰剂组173例,HR 0.99(95%CI 0.80-1.22;P=0.94)。
  • 高危长程试验(基线LDL≥100 mg/dL,中位随访12个月)主要心血管事件bococizumab组179例 vs 安慰剂组224例,HR 0.79(95%CI 0.65-0.97;P=0.02)。
  • 合并两项试验主要终点HR 0.88(95%CI 0.76-1.02;P=0.08)。
  • 注射部位反应bococizumab组10.4% vs 安慰剂组1.3%(P<0.001)。

证据类型、等级与局限

  • 证据类型:两项平行、跨国随机对照试验(SPIRE-1和SPIRE-2)。
  • 局限:试验因申办方决定停止bococizumab开发而提前终止,部分原因是其他研究数据显示高滴度抗药抗体发生率;低危短程试验中位随访7个月,高危长程试验中位随访12个月,合并试验中位随访10个月。

对床旁实践的改变

  • 作者认为,在低危患者试验中bococizumab对主要心血管事件无获益,而在高危患者试验中有显著获益。
  • 因出现高滴度抗药抗体,申办方决定停止bococizumab开发,试验提前终止,bococizumab未进入临床常规使用。

指南或共识出处

  • SPIRE-1(NCT01975376)和SPIRE-2(NCT01975389)试验,由辉瑞(Pfizer)资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk.

METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months.

RESULTS: At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P=0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P=0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P=0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001).

CONCLUSIONS: In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients. (Funded by Pfizer; SPIRE-1 and SPIRE-2 ClinicalTrials.gov numbers, NCT01975376 and NCT01975389 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med. 2017. PMID: 28304242. doi:10.1056/NEJMoa1701488

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。